Seven Tumor-Associated Autoantibodies as a Eerum Biomarker for Primary Screening of Non-Small Cell Lung Cancer

Seven Tumor-Associated Autoantibodies as a Eerum Biomarker for Primary Screening of Non-Small Cell Lung Cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Seven Tumor-Associated Autoantibodies as a Eerum Biomarker for Primary Screening of Non-Small Cell Lung Cancer Chen Tingting, Lu Wei, Chen Ping This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-321719/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objective : Tumor-associated autoantibodies (TAAbs) are produced by the organism in response to peptides at the surface of tumor cells or proteins released by tumors. The purpose of this study is to analyze the expression of TAAbs in different pathological stages and determine their diagnostic value in early non-small cell lung cancer (NSCLC). Methods : We retrospectively analyzed the expression of 7-TAAbs in 216 newly diagnosed NSCLC patients, 202 patients with lung benign diseases and 137 healthy cases. The expression of a panel of 7-TAAbs, including p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2, GBU4-5, was measured by ELISA. Results : The serum levels of p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2 and GBU4-5 were not statistically significant (P>0.05) in NSCLC, benign and healthy groups. The area under the curve (AUC) of 7-TAAbs were all lower than 0.70. The sensitivity of combined detection was the highest (26.39%), while the specificity was the lowest (88.62%). PGP9.5, SOX2, GAGE7, MAGE A1 and combined detection were significantly different among the three groups (P < 0.05). PGP9.5, GAGE7, MAGE A1 and combined detection were significantly different between the NSCLC and benign groups (P < 0.05). PGP9.5, SOX2, GAGE7 and combined detection were significantly different between the NSCLC and healthy groups (P < 0.05). The positive rate of the combined detection of 7-TAAbs was 44.44% in NSCLC stage IV, while that in the other three stages was less than 30.00%. Conclusions : The sensitivity of 7-TAAbs in early NSCLC was not high, so it cannot be used alone as a screening method for NSCLC. In view of the differences of positive rate between the NSCLC and non- NSCLC groups, 7-TAAbs can be used as a supplementary mean of NSCLC screening. Oncology Tumor-associated autoantibodies NSCLC screening method sensitivity Figures Figure 1 Figure 2 Figure 3 Figure 4 Full Text Due to technical limitations, full-text HTML conversion of this manuscript could not be completed. However, the latest manuscript can be downloaded and accessed as a PDF. Tables Table 1. The clinical features of the NSCLC group group NSCLC group %（n） Pathological classification Adenocarcinoma 83.56（183） Squamous carcinoma 13.89（30） Adenosquamous carcinoma 1.39 (3) Pathological stage Stage I 75.46（163） Stage II 6.48（14） Stage III 5.46（12） Stage IV 12.50（27） Typical respiratory symptoms Cough 17.59（38） Expectoration 9.26（20） Chest pain 4.17（9） Chest tightness 8.33（18） Regional lymph node status N0 81.48（176） N1 3.70（8） N2 4.63（10） N3 10.19（22） Distant metastasis status No distant metastasis 87.04 (188) Distant metastasis 12.50 (27) Unable to evaluate 0.46 (1) Table 2. The diagnostic efficiency of 7-TAAbs in NSCLC p53 PGP9.5 SOX2 GAGE7 GUB4-5 MAGE A1 CAGE Combined Sen (%) 2.31 3.24 3.70 7.87 10.65 4.17 2.78 26.39 Spe (%) 98.50 100.00 99.10 98.20 92.81 99.40 98.80 88.62 PPV (%) 50.00 100.00 72.73 73.91 48.94 81.82 60.00 60.00 NPV (%) 60.93 61.51 61.41 62.24 61.63 61.60 61.11 65.05 Sen: Sensitivity; Spe: Specificity; PPV: positive predictive value; NPV: negative predictive value. Table 3. Comparison of positive rate of 7-TAAbs among the NSCLC, benign and healthy groups Total index χ2 P P1 P2 P3 P53 1.153 0.562 - - - PGP9.5 11.126 0.004* 0.015* 0.046* - SOX2 6.323 0.042* 0.223 0.025* 0.275 GAGE7 13.835 0.001* 0.001* 0.020* 0.689 GUB4-5 2.435 0.296 - - - MAGE A1 9.584 0.008* 0.004* 0.214 0.163 CAGE 2.006 0.367 - - - Combined 24.321 <0.001* <0.001 0.002* 0.354 P is the comparison among the NSCLC, benign and healthy groups. P1 is the comparison between the NSCLC and benign groups. P2 is the comparison between the NSCLC and healthy groups. P3 is the comparison between the benign and healthy groups. *P <0.05 was statistically different among the three groups. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-321719","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research","associatedPublications":[],"authors":[{"id":16563966,"identity":"bf7a5c66-d205-479c-a5d3-ac9b792844d7","order_by":0,"name":"Chen Tingting","email":"","orcid":"","institution":"Zhejiang University of Traditional Chinese Medicine First Affiliated Hospital: Zhejiang Hospital of Traditional Chinese Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Chen","middleName":"","lastName":"Tingting","suffix":""},{"id":16563967,"identity":"0a1c5e19-02d2-4c59-9799-39f819b59823","order_by":1,"name":"Lu Wei","email":"","orcid":"","institution":"Zhejiang University of Traditional Chinese Medicine First Affiliated Hospital: Zhejiang Hospital of Traditional Chinese Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Lu","middleName":"","lastName":"Wei","suffix":""},{"id":16563968,"identity":"dce891bb-80a1-48c6-9e74-6311a60ae540","order_by":2,"name":"Chen Ping","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAzElEQVRIiWNgGAWjYHAC5gcJP9jkYBwiNLAxsxl87OEzJkkLg+QMNrnEBqK18M/vP2DMw2OWPr/9dJoEQ4V1YgP72QN4tUgcY2Z4zGORltvYk7tNguFMemIDT14CXi0GQIcBbTmW2yzBu02Cse1wYoMEjwFBLdI8bP/T2cBa/hGpBeh9tgQesJYGIrRIHEs2AwYym+EMntzNFgnH0o3beHLwa+FvPvgYFJXy8u1nN974UGMt289+Br8WVJAAxGwkqB8Fo2AUjIJRgAMAAOeVOnhU0s7eAAAAAElFTkSuQmCC","orcid":"","institution":"Zhejiang University of Traditional Chinese Medicine First Affiliated Hospital: Zhejiang Hospital of Traditional Chinese Medicine","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Chen","middleName":"","lastName":"Ping","suffix":""}],"badges":[],"createdAt":"2021-03-12 14:05:25","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-321719/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-321719/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":7076855,"identity":"efe506c3-8dfb-4343-aa3f-b3d1b1de5e40","added_by":"auto","created_at":"2021-03-17 21:07:57","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":64030,"visible":true,"origin":"","legend":"Comparative analysis of 7-TAAbs expression between NSCLC, benign and healthy groups\na. Expression of p53 in NSCLC, benign and healthy groups; b. PGP9.5 expression in NSCLC, benign and healthy groups; \nc. SOX2 expression in NSCLC, benign and healthy groups; d. GAGE7 expression in NSCLC, benign and healthy groups; \ne. GUB4-5 expression in NSCLC, benign and healthy groups; f. MAGE A1 expression in NSCLC, benign and healthy groups; \ng. CAGE expression in NSCLC, benign and healthy groups.\n","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-321719/v1/344d31ae166649c96b8f8aa0.png"},{"id":7077139,"identity":"cd29431b-9d1c-40c7-bcb3-1093ccd597e7","added_by":"auto","created_at":"2021-03-17 21:10:57","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":41453,"visible":true,"origin":"","legend":"The ROC curve of 7-TAAbs in NSCLC diagnosis","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-321719/v1/df4c0db053e86dde03691e7e.png"},{"id":7077236,"identity":"2e2de3c7-5ea9-4b3f-a8d0-edc0c2c9c45d","added_by":"auto","created_at":"2021-03-17 21:13:57","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":13614,"visible":true,"origin":"","legend":"The positive rates of 7-TAAbs in the three groups (%)","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-321719/v1/c3088045fa38355a600cb5a4.png"},{"id":7077140,"identity":"38f8b97c-9a1b-4eac-95f8-9f3ca53675e5","added_by":"auto","created_at":"2021-03-17 21:10:57","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":44749,"visible":true,"origin":"","legend":"The positive rate of 7-TAAbs in the NSCLC group","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-321719/v1/9e69a0c8897cf0661e8d85df.png"},{"id":13681553,"identity":"b519cd83-d9c3-47ab-9b75-e1da0fc956be","added_by":"auto","created_at":"2021-09-17 11:52:12","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":326457,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-321719/v1/a6f2a95a-4988-4670-8d4e-f7b4c8956b9e.pdf"}],"financialInterests":"","formattedTitle":"\u003cp\u003eSeven Tumor-Associated Autoantibodies as a Eerum Biomarker for Primary Screening of Non-Small Cell Lung Cancer\u003c/p\u003e","fulltext":[{"header":"Full Text","content":"Due to technical limitations, full-text HTML conversion of this manuscript could not be completed. However, the latest manuscript can be downloaded and \u003ca href='/article/rs-321719/latest.pdf' target='_blank'\u003e accessed as a PDF.\u003c/a\u003e"},{"header":"Tables","content":"\u003cp\u003eTable 1. The clinical features of the NSCLC group\u003c/p\u003e\n\u003ctable border=\"1\" width=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" colspan=\"2\" width=\"336\"\u003e\n\u003cp\u003egroup\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003eNSCLC group\u0026nbsp;\u0026nbsp;\u0026nbsp; %（n）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 109px;\" rowspan=\"3\" width=\"128\"\u003e\n\u003cp\u003ePathological classification\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eAdenocarcinoma\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e83.56（183）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eSquamous carcinoma\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e13.89（30）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 35px;\"\u003e\n\u003ctd style=\"height: 35px;\" width=\"209\"\u003e\n\u003cp\u003eAdenosquamous carcinoma\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 35px;\" width=\"196\"\u003e\n\u003cp\u003e1.39 (3)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 148px;\" rowspan=\"4\" width=\"128\"\u003e\n\u003cp\u003ePathological stage\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eStage I\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e75.46（163）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eStage II\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e6.48（14）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eStage III\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e5.46（12）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eStage IV\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e12.50（27）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 148px;\" rowspan=\"4\" width=\"128\"\u003e\n\u003cp\u003eTypical respiratory symptoms\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eCough\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e17.59（38）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eExpectoration\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e9.26（20）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eChest pain\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e4.17（9）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eChest tightness\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e8.33（18）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 148px;\" rowspan=\"4\" width=\"128\"\u003e\n\u003cp\u003eRegional lymph node status\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eN0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e81.48（176）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eN1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e3.70（8）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eN2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e4.63（10）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 37px;\"\u003e\n\u003ctd style=\"height: 37px;\" width=\"209\"\u003e\n\u003cp\u003eN3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 37px;\" width=\"196\"\u003e\n\u003cp\u003e10.19（22）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 35px;\"\u003e\n\u003ctd style=\"height: 105px;\" rowspan=\"3\" width=\"128\"\u003e\n\u003cp\u003eDistant metastasis status\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 35px;\" width=\"209\"\u003e\n\u003cp\u003eNo distant metastasis\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 35px;\" width=\"196\"\u003e\n\u003cp\u003e87.04 (188)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 35px;\"\u003e\n\u003ctd style=\"height: 35px;\" width=\"209\"\u003e\n\u003cp\u003eDistant metastasis\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 35px;\" width=\"196\"\u003e\n\u003cp\u003e12.50 (27)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr style=\"height: 35px;\"\u003e\n\u003ctd style=\"height: 35px;\" width=\"209\"\u003e\n\u003cp\u003eUnable to evaluate\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd style=\"height: 35px;\" width=\"196\"\u003e\n\u003cp\u003e0.46 (1)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003ctable border=\"1\" width=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"15\" width=\"578\"\u003e\n\u003cp\u003eTable 2. The diagnostic efficiency of 7-TAAbs in NSCLC\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"78\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"56\"\u003e\n\u003cp\u003ep53\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"59\"\u003e\n\u003cp\u003ePGP9.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"58\"\u003e\n\u003cp\u003eSOX2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"53\"\u003e\n\u003cp\u003eGAGE7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"62\"\u003e\n\u003cp\u003eGUB4-5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"77\"\u003e\n\u003cp\u003eMAGE A1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003eCAGE\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"80\"\u003e\n\u003cp\u003eCombined\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"78\"\u003e\n\u003cp\u003eSen (%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"56\"\u003e\n\u003cp\u003e2.31\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"59\"\u003e\n\u003cp\u003e3.24\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"58\"\u003e\n\u003cp\u003e3.70\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"53\"\u003e\n\u003cp\u003e7.87\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"62\"\u003e\n\u003cp\u003e10.65\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"77\"\u003e\n\u003cp\u003e4.17\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e2.78\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"80\"\u003e\n\u003cp\u003e26.39\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"78\"\u003e\n\u003cp\u003eSpe (%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"56\"\u003e\n\u003cp\u003e98.50\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"59\"\u003e\n\u003cp\u003e100.00\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"58\"\u003e\n\u003cp\u003e99.10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"53\"\u003e\n\u003cp\u003e98.20\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"62\"\u003e\n\u003cp\u003e92.81\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"77\"\u003e\n\u003cp\u003e99.40\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e98.80\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"80\"\u003e\n\u003cp\u003e88.62\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"78\"\u003e\n\u003cp\u003ePPV (%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"56\"\u003e\n\u003cp\u003e50.00\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"59\"\u003e\n\u003cp\u003e100.00\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"58\"\u003e\n\u003cp\u003e72.73\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"53\"\u003e\n\u003cp\u003e73.91\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"62\"\u003e\n\u003cp\u003e48.94\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"77\"\u003e\n\u003cp\u003e81.82\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e60.00\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"80\"\u003e\n\u003cp\u003e60.00\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"78\"\u003e\n\u003cp\u003eNPV (%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"56\"\u003e\n\u003cp\u003e60.93\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"59\"\u003e\n\u003cp\u003e61.51\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"58\"\u003e\n\u003cp\u003e61.41\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"53\"\u003e\n\u003cp\u003e62.24\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"62\"\u003e\n\u003cp\u003e61.63\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"77\"\u003e\n\u003cp\u003e61.60\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e61.11\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"80\"\u003e\n\u003cp\u003e65.05\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"15\" width=\"578\"\u003e\n\u003cp\u003eSen: Sensitivity; Spe: Specificity; PPV: positive predictive value; NPV: negative predictive value.\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003ctable border=\"1\" width=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"14\" width=\"591\"\u003e\n\u003cp\u003eTable 3. Comparison of positive rate of 7-TAAbs among the NSCLC, benign and healthy groups\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"92\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" width=\"181\"\u003e\n\u003cp\u003eTotal\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"93\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"106\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"92\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"92\"\u003e\n\u003cp\u003eindex\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"90\"\u003e\n\u003cp\u003e\u0026chi;2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"91\"\u003e\n\u003cp\u003e\u003cem\u003eP \u003c/em\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"93\"\u003e\n\u003cp\u003e\u003cem\u003eP1\u003c/em\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"106\"\u003e\n\u003cp\u003e\u003cem\u003eP2\u003c/em\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"92\"\u003e\n\u003cp\u003e\u003cem\u003eP3\u003c/em\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"92\"\u003e\n\u003cp\u003eP53\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"90\"\u003e\n\u003cp\u003e1.153\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"91\"\u003e\n\u003cp\u003e0.562\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"93\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"106\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"92\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"92\"\u003e\n\u003cp\u003ePGP9.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"90\"\u003e\n\u003cp\u003e11.126\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"91\"\u003e\n\u003cp\u003e0.004*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"93\"\u003e\n\u003cp\u003e0.015*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"106\"\u003e\n\u003cp\u003e0.046*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"92\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"92\"\u003e\n\u003cp\u003eSOX2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"90\"\u003e\n\u003cp\u003e6.323\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"91\"\u003e\n\u003cp\u003e0.042*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"93\"\u003e\n\u003cp\u003e0.223\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"106\"\u003e\n\u003cp\u003e0.025*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"92\"\u003e\n\u003cp\u003e0.275\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"92\"\u003e\n\u003cp\u003eGAGE7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"90\"\u003e\n\u003cp\u003e13.835\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"91\"\u003e\n\u003cp\u003e0.001*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"93\"\u003e\n\u003cp\u003e0.001*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"106\"\u003e\n\u003cp\u003e0.020*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"92\"\u003e\n\u003cp\u003e0.689\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"92\"\u003e\n\u003cp\u003eGUB4-5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"90\"\u003e\n\u003cp\u003e2.435\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"91\"\u003e\n\u003cp\u003e0.296\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"93\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"106\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"92\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"92\"\u003e\n\u003cp\u003eMAGE A1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"90\"\u003e\n\u003cp\u003e9.584\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"91\"\u003e\n\u003cp\u003e0.008*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"93\"\u003e\n\u003cp\u003e0.004*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"106\"\u003e\n\u003cp\u003e0.214\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"92\"\u003e\n\u003cp\u003e0.163\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"92\"\u003e\n\u003cp\u003eCAGE\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"90\"\u003e\n\u003cp\u003e2.006\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"91\"\u003e\n\u003cp\u003e0.367\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"93\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"106\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"92\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"92\"\u003e\n\u003cp\u003eCombined\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"90\"\u003e\n\u003cp\u003e24.321\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"91\"\u003e\n\u003cp\u003e\u0026lt;0.001*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"93\"\u003e\n\u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"106\"\u003e\n\u003cp\u003e0.002*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"92\"\u003e\n\u003cp\u003e0.354\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"14\" width=\"591\"\u003e\n\u003cp\u003e\u003cem\u003eP\u003c/em\u003e is the comparison among the NSCLC, benign and healthy groups. \u003cem\u003eP1 \u003c/em\u003eis the comparison between the NSCLC and benign groups.\u003cem\u003e P2 \u003c/em\u003eis the comparison between the NSCLC and healthy groups. \u003cem\u003eP3 \u003c/em\u003eis the comparison between the benign and healthy groups. \u003cem\u003e*P\u003c/em\u003e\u0026lt;0.05 was statistically different among the three groups.\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Tumor-associated autoantibodies, NSCLC, screening method, sensitivity ","lastPublishedDoi":"10.21203/rs.3.rs-321719/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-321719/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eObjective\u003c/strong\u003e: Tumor-associated autoantibodies (TAAbs) are produced by the organism in response to peptides at the surface of tumor cells or proteins released by tumors. The purpose of this study is to analyze the expression of TAAbs in different pathological stages and determine their diagnostic value in early non-small cell lung cancer (NSCLC). \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: We retrospectively analyzed the expression of 7-TAAbs in 216 newly diagnosed NSCLC patients, 202 patients with lung benign diseases and 137 healthy cases. The expression of a panel of 7-TAAbs, including p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2, GBU4-5, was measured by ELISA. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e: The serum levels of p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2 and GBU4-5 were not statistically significant (P\u0026gt;0.05) in NSCLC, benign and healthy groups. The area under the curve (AUC) of 7-TAAbs were all lower than 0.70. The sensitivity of combined detection was the highest (26.39%), while the specificity was the lowest (88.62%). PGP9.5, SOX2, GAGE7, MAGE A1 and combined detection were significantly different among the three groups (P \u0026lt; 0.05). PGP9.5, GAGE7, MAGE A1 and combined detection were significantly different between the NSCLC and benign groups (P \u0026lt; 0.05). PGP9.5, SOX2, GAGE7 and combined detection were significantly different between the NSCLC and healthy groups (P \u0026lt; 0.05). The positive rate of the combined detection of 7-TAAbs was 44.44% in NSCLC stage IV, while that in the other three stages was less than 30.00%. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConclusions\u003c/strong\u003e: The sensitivity of 7-TAAbs in early NSCLC was not high, so it cannot be used alone as a screening method for NSCLC. In view of the differences of positive rate between the NSCLC and non- NSCLC groups, 7-TAAbs can be used as a supplementary mean of NSCLC screening.\u003c/p\u003e","manuscriptTitle":"Seven Tumor-Associated Autoantibodies as a Eerum Biomarker for Primary Screening of Non-Small Cell Lung Cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2021-03-17 21:07:55","doi":"10.21203/rs.3.rs-321719/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"d9fc837c-51cf-4158-9701-b92e6fb4f241","owner":[],"postedDate":"March 17th, 2021","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":3034461,"name":"Oncology"}],"tags":[],"updatedAt":"2021-04-25T03:05:51+00:00","versionOfRecord":[],"versionCreatedAt":"2021-03-17 21:07:55","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-321719","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-321719","identity":"rs-321719","version":["v1"]},"buildId":"rHA-KDH7Qsr4HCuvH75dn","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}